NCT03803605View on ClinicalTrials.gov

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

January 28, 2021

Study Completion Date

January 28, 2021

Conditions
HIV-1 Infection
Interventions
BIOLOGICAL

VRC07-523LS

VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)

DRUG

Vorinostat (VOR)

Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)

Trial Locations (1)

27514

University of North Carolina Health Care, Chapel Hill

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT03803605 - Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons | Biotech Hunter | Biotech Hunter